A Non-interventional, Multi-center, Observational Post Authorization Safety Study of Patients With Relapse/Refractory Multiple Myeloma Treated With Lenalidomide in Turkey
Phase of Trial: Phase IV
Latest Information Update: 11 Apr 2017
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 27 Sep 2016 Planned number of patients changed from 250 to 500.
- 27 Sep 2016 Planned End Date changed from 1 Apr 2020 to 1 Jul 2021.
- 27 Sep 2016 Planned primary completion date changed from 1 Apr 2018 to 1 Jul 2020.